The latest announcement is out from Grand Pharmaceutical Group Limited ( (HK:0512) ).
Grand Pharmaceutical Group Limited announced the approval for commercialization of its first generic fluticasone propionate nasal spray in China, marking a significant milestone in its respiratory product line. This approval addresses a substantial unmet need in the Chinese market for allergic rhinitis treatment, a condition affecting nearly 250 million people in China. The product’s inclusion in the National Medical Insurance Catalogue and the National Essential Medicines Catalogue highlights its potential impact. The company aims to break the market monopoly of foreign-funded products and strengthen its position in the respiratory disease treatment market.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a company focused on the pharmaceutical industry, specializing in the development and commercialization of products for respiratory and critical diseases. The company offers a comprehensive product portfolio for conditions such as rhinitis, bronchitis, pneumonia, asthma, and chronic obstructive pulmonary disease, and is committed to innovation and global expansion.
YTD Price Performance: 21.13%
Average Trading Volume: 8,903,929
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$19.74B
Learn more about 0512 stock on TipRanks’ Stock Analysis page.